Release Summary

Calyxt Patent Encompassing Broad Uses of Plant Gene Editing Technologies Maintained by USPTO. U.S. Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as ZFN, TALEN & CRISPR/Cas9

Calyxt, Inc.